Post by Roche

Liver disease is often asymptomatic until late stage. In Hong Kong — where at least three in 10 people are projected to be living with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — the sheer scale of the health burden creates a fundamental challenge. But what if we could catch the disease early enough to change the outcome, before it progresses to hepatocellular carcinoma (HCC)? Comprehensive evaluation including new, more sensitive biomarkers can transform liver health outcomes. Read the article to learn more 👉 https://spkl.io/604378N6J #RocheDiaAPAC #OneLiverAPAC #LiverHealth #HealthEquity"